skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Regorafenib (Code C78204)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Regorafenib

Definition: An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.

Display Name: Regorafenib

Label: Regorafenib

NCI Thesaurus Code: C78204 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2980094  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BAY 73-4506

External Source Codes: 
CAS Registry Number 755037-03-7 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 595192
PDQ Open Trial Search ID 595192 (check for NCI PDQ open clinical trial info)
UMLS CUI C2980094

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C21H15ClF4N4O3
code C78204
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Multitargeted_Receptor_Tyrosine_Kinase_Inhibitor_BAY_73-4506
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom